Creative Medical Technology
CELZ
11 hedge funds and large institutions have $437K invested in Creative Medical Technology in 2025 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
514% more capital invested
Capital invested by funds: $71.2K → $437K (+$366K)
38% more funds holding
Funds holding: 8 → 11 (+3)
6.23% more ownership
Funds ownership: 1.71% → 7.94% (+6.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$516K |
| 2 |
HF
HRT Financial
New York
|
+$45.5K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$27.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.25K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$3.94K |
Top Sellers
CELZ Hedge Fund Activity: Q1 2025 in Review
11 of the 7,469 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q1 2025, worth a combined $437K — up 514% from $71.2K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new CELZ positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $516K.
- 11 institutional investors held Creative Medical Technology (CELZ) as of Q1 2025, up from 8 in Q4 2024.
- Funds reported $437K of Creative Medical Technology stock for Q1 2025, up 514% quarter-over-quarter.
- 3 funds opened new Creative Medical Technology positions in Q1 2025 and 0 closed out, a net change of +3 holders.
- The largest Creative Medical Technology buyer in Q1 2025 was Armistice Capital, an estimated $516K added.
Based on aggregated 13F filings for Q1 2025.